Código QR (código de barras bidimensional)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Abstract Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation EGFR tyrosine kinase inhibitor (EGFR-TKIs),...

תיאור מלא

שמור ב:
Principais autores: Xingxiang Pu, Yu Zhou, Yi Kong, Bolin Chen, Aifang Yang, Jia Li, Kang Li, Yan Xu, Lin Wu
פורמט: Artigo
שפה:Inglês
יצא לאור: BMC 2023-10-01
סדרה:BMC Cancer
נושאים:
Uncommon EGFR mutation
Non-small cell lung cancer
Dacomitinib
Efficacy
Safety
גישה מקוונת:https://doi.org/10.1186/s12885-023-11465-2
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים